Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days

Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s

Digest more
 · 16h · on MSN
Novo Nordisk Alzheimer's drug trials fail in blow to weight-loss giant
Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the progression of the brain-wasting disease, the firm said on Monday, sending the obesity drugmaker's shares sliding.

Continue reading

 · 16h · on MSN
Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s as hoped, but don’t call it a failure
 · 14h · on MSN
Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says
1h

Here’s why the Novo Nordisk stock has crashed by 70%

Novo Nordisk stock price has suffered a harsh reversal this year as the company’s woes have escalated. What next for the stock?
16h

Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk

Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers ...
21hon MSN

Analysts, investors say Alzheimer's miss adds to Novo's challenges, but fundamentals intact

Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...
3d

Novo Nordisk: The Sell-Off Is Getting Absolutely Ridiculous

Novo has experienced a prolonged sell.off over the last months, declining more than 65% from all-time highs. Why some kind of ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
Feedback
  • Privacy
  • Terms